ERBB4 and gastric cancer: Multivariate Cox regression analysis indicated that gene amplification may be served as a predictor of poor prognosis for gastric cancer patients (ERBB4: HR = 2.00, 95% CI = 1.02–3.86, P = 0.04; C-MET: HR = 2.10, 95% CI = 1.20–3.69, P = 0.01; CD44: HR = 2.59, 95% CI = 1.34–5.01, P = 0.005) as an independently variable with respect to gender, age, differentiation, lymph node metastasis, and tumor stage (Table 3).